Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care
RAHWAY, NJ / ACCESSWIRE / November 20, 2024 / The Merck Foundation (Foundation) has announced a new initiative to help...
Pharmaceutical
Converge Bio raises $5.5M Seed to speed up drug discovery and development with Generative AI
TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- Converge Bio, a generative AI platform for accelerated drug discovery and development, today...
MOBILion Systems Launches Proteomics Advisory Board
CHADDS FORD, Pa., Nov. 20, 2024 /PRNewswire/ -- Today MOBILion Systems, Inc., a leader in separation science innovation, announced the formation...
World Class Health Secures $8M in Seed Funding to Expand Concierge Health Benefit with the largest Global Centers of Excellence network
World Class Health's pioneering benefit has achieved a stellar 1.6% readmission rate and delivered a 90+ NPS from nearly 4,000...
VMS BioMarketing Changes its Name to Momentum Life Sciences, Reinforcing its Commitment to Patient Engagement
INDIANAPOLIS, Nov. 20, 2024 /PRNewswire/ -- VMS BioMarketing, a leading provider of patient engagement solutions, today announced its name change...
CND Life Sciences Receives Grant from The Michael J. Fox Foundation to Study Quantification of Cutaneous Phosphorylated Alpha-Synuclein (P-SYN) in People with Parkinson’s Disease
Grant funding will support the new Syn-Q Clinical Study to further investigate the quantification of P-SYN in skin biopsies using CND's...
Teva Takes on Antimicrobial Resistance (AMR): What You Need to Know
NORTHAMPTON, MA / ACCESSWIRE / November 20, 2024 / Antimicrobial resistance (AMR) happens when bacteria no longer respond to antibiotics,...
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in...
Safe Supply Streaming Co Ltd. Announces Closing of Acquisition of Drug Lab 118 Ltd
Toronto, Ontario--(Newsfile Corp. - November 20, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe...
Safe Supply Streaming Co Ltd. Announces Closing of Acquisition of Drug Lab 118 Ltd
Toronto, Ontario--(Newsfile Corp. - November 20, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe...
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression...
BioSyent Releases Financial Results for Q3 and YTD 2024
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for...
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical...
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Unnatural Products Appoints Simon Bailey, Ph.D., as Chief Operating Officer and President of R&D
Simon Bailey, Ph.D., Chief Operating Officer and President of R&D, Unnatural Products SANTA CRUZ, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE)...
Enlivex Adopts Bitcoin Treasury Reserve Strategy
Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS)
Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase...
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials...
OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference
MIAMI, Nov. 20, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in...
BioSyent Declares Fourth Quarter 2024 Dividend
MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce...